Paul Choi
Stock Analyst at Goldman Sachs
(3.46)
# 861
Out of 4,893 analysts
108
Total ratings
52.11%
Success rate
4.03%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $17.15 | -30.03% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $14.08 | -78.69% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $1.35 | +492.59% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $9.31 | -46.29% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $8.00 | - | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $32.70 | +59.02% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $6.14 | +242.02% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.97 | +33.85% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $1.21 | +147.93% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $10.98 | -8.93% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $175.09 | +28.51% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $84.93 | +68.37% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $49.11 | -14.48% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $36.72 | +63.40% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $16.11 | +17.96% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $28.72 | +11.42% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $46.27 | +8.06% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.27 | +260.24% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $6.63 | +654.15% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.26 | +1,884.13% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $14.70 | +1,056.46% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.58 | +123.46% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $30.00 | +10.02% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $134.46 | +0.40% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $23.25 | +1,190.32% | 2 | Mar 30, 2020 |
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $17.15
Upside: -30.03%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $14.08
Upside: -78.69%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.35
Upside: +492.59%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $9.31
Upside: -46.29%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $8.00
Upside: -
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $32.70
Upside: +59.02%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $6.14
Upside: +242.02%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.97
Upside: +33.85%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $1.21
Upside: +147.93%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.98
Upside: -8.93%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $175.09
Upside: +28.51%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $84.93
Upside: +68.37%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $49.11
Upside: -14.48%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $36.72
Upside: +63.40%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $16.11
Upside: +17.96%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $28.72
Upside: +11.42%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $46.27
Upside: +8.06%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.27
Upside: +260.24%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $6.63
Upside: +654.15%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.26
Upside: +1,884.13%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $14.70
Upside: +1,056.46%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.58
Upside: +123.46%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $30.00
Upside: +10.02%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $134.46
Upside: +0.40%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $23.25
Upside: +1,190.32%